Pfizer extends King tender offer until January
NEW YORK (Reuters) - Pfizer Inc (PFE.N) is extending its offer to buy King Pharmaceuticals Inc KG.N to January 21, the world's largest drugmaker said on Wednesday.
About 47 percent of outstanding King shares were tendered as of December 14, Pfizer said.
Pfizer agreed in October to buy King for $3.6 billion to shore up earnings ahead of the evaporation of revenue from Lipitor, its biggest product.
Pfizer, which is digesting last year's $67 billion acquisition of Wyeth, said it would use cash to pay $14.25 a share for King -- a 40 percent premium over King's closing share price before the deal was announced.
The deal would expand Pfizer's presence in the market for pain drugs by adding King's pain portfolio to products such as Lyrica and Celebrex.
(Reporting by Ransdell Pierson. Editing by Robert MacMillan)
TOKYO - Asian shares drifted lower on Tuesday, with momentum from prior gains fading as investors were left short of cues with the U.S. markets closed on Monday, while the euro continued to probe one-year lows in the uncertainty over the European Central Bank's policy decision later this week.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.